The aim of this study was to investigate whether there was a significant difference in high-level aminoglycoside resistance (HLAR) between vancomycin-sensitive enterococci (VSE) and vancomycinresistant enterococci (VRE). Vancomycin resistance was determined in 116 Enterococcus isolates using brain-heart infusion agar containing 6 µg/ml vancomycin. HLAR was determined by both standard agar screening and disk diffusion methods. Streptomycin and gentamicin were used as predictors of HLAR. Vancomycin resistance and HLAR were found in 17 (14.7%) and 41 (35.3%) of the Enterococcus strains, respectively. HLAR was found in 11 of 17 VRE and 30 of 98 VSE strains. HLAR in VRE strains was significantly higher than in VSE. More enterococcal strains were found to be resistant to both gentamicin and streptomycin (29) than to gentamicin (one) or streptomycin (11) alone. The HLAR rate in VRE was two-fold higher than in VSE. The synergistic bactericidal effect of aminoglycosides and b-lactam or glycopeptide antibiotics is lost if there is high-level resistance to aminoglycosides.
Introduction
Enterococci are found in the intestine of nearly all animals and humans, 1 and are the second most common cause of nosocomial infection. 2 Of the 20 or more enterococcal species, only Enterococci faecalis and Enterococci faecium commonly colonize and infect humans in detectable numbers. 3 E. faecalis is isolated from approximately 80% of human infections, such as nosocomial bacteraemia, surgical wound infection and urinary tract infection, and E. faecium is isolated from most of the remainder. The pathogenesis due to enterococci has been linked to their increasing antimicrobial resistance. 3 Infections caused by other enterococcal species are rare. 4 Despite their ubiquity and frequent isolation, they have not been thought to cause serious disease because they lack common virulence factors. Now, however, enterococci are regarded as true pathogens and are the second leading cause of nosocomial infection. 2 β-lactam and aminoglycoside antibiotics are generally the antibiotics of choice for treating the serious infections caused by enterococci. During the past decade, however, use of glycopeptides has been increasing. Several studies 2,4 -6 indicate that high-level aminoglycoside resistance (HLAR) and vancomycin resistance patterns are becoming increasingly important. The minimum inhibitory concentration (MIC) criteria for gentamicin and streptomycin high-level resistance vary from > 500 µg/ml to 2000 µg/ml. 7 High-level gentamicin resistance is predominantly the result of the presence of the inactivating enzyme 2′′-phosphotransferase-6′-acetyltransferase, which confers resistance to gentamicin, tobramycin, netilmicin, amikacin and kanamycin. 8 Gentamicin resistance is a good predictor of resistance to other aminoglycosides, except streptomycin. Studies have demonstrated that two types of streptomycin resistance occur in enterococci. 6, 8 As aminoglycosides have poor activity against enterococci with MICs normally in the range 8 -256 µg/ml, they cannot be used as single agents for therapy. This intrinsic, moderate-level resistance is due to poor uptake of the aminoglycoside. 9 Moderate-level resistance, due to low permeability of the enterococcus cell membrane, which can be overcome with a penicillin (which increases the cellular uptake of the aminoglycoside), and highlevel resistance streptomycin (> 2000 µg/ml), which is either ribosomally mediated or due to the production of aminoglycosideinactivating (adenyltransferase) enzymes. 6, 8 Strains with high-level streptomycin resistance remain susceptible to gentamicin.
As enterococcal strains resistant to gentamicin and streptomycin occur by different mechanisms, it is important to determine the susceptibilities of organisms to both agents. This is due to a synergistic bactericidal effect that exists between aminoglycosides and β-lactam or glycopeptide antibiotics, but is lost if there is high-level resistance to aminoglycosides. Resistance to high concentrations of aminoglycoside antibiotics is usually mediated by aminoglycosidemodifying enzymes, 8 and is widespread among enterococci. 1, 8, 10 Enterococci resistant to vancomycin have emerged as a significant problem in the healthcare system. 11 Glycopeptide antibiotics exert their effect by inhibiting bacterial cell-wall synthesis; bacteria resistant to these antibiotics manufacture cell-wall precursors with decreased affinity for the glycopeptide, which prevents the antibiotic from blocking cell-wall synthesis. 12 Enterococci frequently express resistance to multiple antibiotics, including ampicillin and aminoglycosides (including high-level resistance), thereby causing therapeutic problems. 4,13 -16 This study was designed to investigate enterococci, and whether there was any correlation between HLAR and vancomycin-sensitive enterococci (VSE) and vancomycin-resistant enterococci (VRE).
Materials and methods
The Atatürk University Aziziye Hospital, Erzurum, Turkey, is a 600-bed healthcare centre providing tertiary care for the city and the surrounding area. In this study, conducted between March and September 2001, rectal swabs were taken from 163 hospitalized patients who were at risk of VRE infection or colonization. The criteria for VRE infection or colonization were: hospitalization for 7 days or more, use of antimicrobials (vancomycin or third-generation cephalosporins), or vancomycin use for 7 days or more. 17 Enterococci were isolated and identified using classic microbiological techniques and the API 20 Strep System (bioMérieux, March-L'Etoile, France), with the software supplied by the manufacturer. Vancomycin resistance was determined by a screening test using a brain-heart infusion agar (BHI) containing 6 µg/ml vancomycin. HLAR was determined by two different methods: standard agar screening and disk diffusion. Standard agar screening was carried out using two BHI agar plates per sample, one of which contained 500 µg/ml gentamicin (Oxoid Ltd, Basingstoke, UK) and the other 2000 µg/ml streptomycin (Oxoid Ltd, Basingstoke, UK).
The disk diffusion screening method was performed on Mueller Hinton Agar using two different antibiotic disks, one of which contained 120 µg/ml gentamicin and the other 300 µg/ml streptomycin. E. faecalis ATCC 51299 and E. faecalis ATCC 29212 were included in the test as reference strains. 7, 18 Results were evaluated according to the National Committee for Clinical Laboratory Standards (NCCLS) criteria, 7 and findings were analysed statistically using the χ 2 test.
Results
Enterococcus species were isolated from 116 (71.2%) of the 163 rectal swabs from patients. Of these 116 isolates, 17 (14.7%) were resistant to vancomycin; that is, 10.4% of the patients were colonized by VRE. The HLAR test results revealed that one enterococcal isolate (0.9%) was resistant to gentamicin only, 11 isolates (9.5%) were resistant to streptomycin only and 29 isolates (25%) were resistant to both antibiotics. In total, 41 isolates (35.3%) showed HLAR to streptomycin and/or gentamicin. There were no significant differences between the two methods used to determine the aminoglycoside resistance rates in the enterococcal isolates.
High-level aminoglycoside resistance in VRE isolates (joint antibiotic resistance) was found significantly more frequently than HLAR in VSE isolates (P < 0.01; Table 1 ).
High-level aminoglycoside resistance to both streptomycin and gentamicin was more common in E. faecium than in E. faecalis strains ( Table 2 ).
Discussion
Vancomycin-resistant enterococci were first reported in 1988. 1 Since then, strains resistant to teicoplanin and/or vancomycin have appeared throughout the world. 19 VRE frequently express additional resistance to multiple antibiotics, including ampicillin and aminoglycosides (including high-level resistance). 19 The emergence of vancomycin resistance in enterococci in addition to the increasing incidence of high-level H Yazgi, M Ertek, S Erol et al.
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enterococcal resistance to penicillin and aminoglycosides presents a serious challenge for physicians treating patients with infections due to these micro-organisms. 8 Over the past decade, isolation of VRE has been reported in nearly all European countries. 8 Comparison of data is very difficult since studies differ considerably in terms of size and type of population studied, as well as in VRE detection methods. Although a low prevalence of VRE faecal carriage in hospitalized patients undergoing normal care has been documented in Sweden (0.0%), Dublin (1.0 -2.0%), The Netherlands (2.0%), Oslo (4.0%), Berlin (1.8%) and Belgium (3.5%), a much higher prevalence has been reported in all patients at risk (patients in the intensive care unit, oncology patients, and those undergoing renal dialysis) in Berlin (16.3%), Belgium (14.0%) and Copenhagen (18.0%). 20 The difficulty of treating infections due to glycopeptide-resistant enterococci (GRE), which might be resistant to all antimicrobial agents used for the treatment of systemic infections, emphasizes the need for detection of acquired GRE rapidly and accurately. This would also help to limit the intra-hospital dissemination of GRE. 16 The prevalence of HLAR is between 15% and 55%, 2 and glycopeptide resistance has become widespread in various geographical areas. 2 Studies in Europe have shown that the geographical distribution of high-level glycoside-resistant enterococci, in general, does not overlap with the distribution of VRE. Some countries, such as the UK, have a high prevalence of VRE and HLGR enterococci, while others, for example Greece, have no VRE, yet have the highest prevalence of HLGR enterococci in Europe. 19 In the present study, HLAR was found to be two-fold higher in VRE isolates than in isolates of VSE. The clinical importance of HLAR in VSE isolates, 4,9 however, is much greater than in other strains because of the lack of synergy among glycopeptide antibiotics and aminoglycosides.
A number of other studies have looked at the rates of resistance in enterococcal species. These include a study of 60 enterococcal strains performed by Cirak and Sultan 10 in 21 in 1997, 10.7% of 421 enterococcal isolates were identified as HLAR, of which 8.2% of E. faecalis and 33.3% of E. faecium isolates were HLAR. All the isolates of E. faecalis were sensitive to vancomycin, but one isolate of E. faecium was vancomycin resistant. Zouain and Araj 5 reported that in Lebanon, high-level resistance to gentamicin and streptomycin was 19% and 36%, respectively, for 111 E. faecalis isolates, and 9% and 26% for 35 E. faecium strains. In Israel, combined resistance to ampicillin, vancomycin and high-level resistance to gentamicin increased from 0 -20% in 1993 -1995 to 38% in 1996. 14 Johnson et al. 22 detected HLGR in 51.7% of 650 vancomycin-resistant E. faecium and in 53.1% of 179 vancomycin-resistant E. faecalis strains, respectively. Another study, carried out in a different geographical location of Turkey from the region where the present study was conducted, found 11.4% of the enterococci isolates were HLAR. 23 In the same study, VRE were not isolated.
These studies show that HLAR prevalence in enterococci is high in many countries, which may pose a serious threat to the treatment of infections due to these bacteria. Furthermore, such resistance may spread to other Grampositive bacteria. HLAR is often associated with resistance to other antimicrobial drugs, which may theoretically result in groups of organisms for which there is no effective antimicrobial treatment. Considering this possible risk, all clinically significant isolates of enterococci should be examined for their antibiotic sensitivity pattern, including HLAR, before the administration of a β-lactam or glycopeptide antibiotic in combination with an aminoglycoside.
